Table 2.

Prevalence and Stability of Insomnia – W1, W2 Cohort

	Prevalence rates		W1, W2 cohort change
	W1 sample %, 95% CI	W1 cohort %, 95% CI	Total incidence %, 95% CI	Chronic %, 95% CI	Remitted %, 95% CI
NRS	18.14	18.23	12.01	40.99	59.01
	(16.85 – 19.43)	(16.75 – 19.71)	(10.77 – 13.25)	(36.48 – 45.49)	(54.51 – 63.52)
DIS	7.05	7.53	3.31	33.35	66.65
	(6.18 – 7.92)	(6.50 – 8.56)	(2.62 – 3.99)	(26.65 – 40.05)	(59.95 – 73.35)
DMS1	3.11	2.93	2.24	19.37	80.63
	(2.54 – 3.67)	(2.31 – 3.54)	(1.69 – 2.79)	(11.22 – 27.52)	(72.48 – 88.78)
DMS2	5.15	5.11	3.90	19.40	80.96
	(4.41 – 5.89)	(4.26 – 5.97)	(3.17 – 4.64)	(12.02 – 26.07)	(73.93 – 87.98)
EMA	3.20	3.27	2.42	14.57	85.43
	(2.61 – 3.78)	(2.60 – 3.93)	(1.84 – 3.01)	(6.86 – 22.27)	(77.73 – 93.14)
P1	26.83	27.12	13.97	45.85	54.15
	(25.36 – 28.30)	(25.42 – 28.82)	(12.65 , 15.29)	(42.15 – 49.54)	(50.46 – 57.85)
P2	6.66	7.03	5.50	34.71	65.29
	(5.84 – 7.49)	(6.05 – 8.01)	(4.63 – 6.37)	(27.73 – 41.69)	(58.31 – 72.27)
P3	4.70	4.94	5.36	23.63	76.37
	(4.02 – 5.39)	(4.14 – 5.75)	(4.50 – 6.22)	(16.39 – 30.88)	(69.12 – 83.61)

NRS refers to nonrestorative sleep; DIS, trouble falling asleep; DMS ₁, nighttime waking, difficult to sleep again; DMS ₂, nighttime waking, but return to sleep; EMA, early morning awakening; P₁, 1 or more insomnia symptoms; P₂, at least 1 symptom and daytime fatigue/sleepiness; P₃, P₂ after mood, anxiety, and substance use disorders are excluded. No significant differences were found comparing W1 sample and W1 cohort with respect to NRS, DIS, DMS1, DMS2, and EMA.